Quetiapine Vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder - Tabular View

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Quetiapine Vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder

This study has been completed.

Study NCT00018642. Last updated on June 23, 2005. Information provided by Department of Veterans Affairs

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields
Brief Title ^†	Quetiapine Vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder
Official Title ^†	Predicting the Optimal Pharmacotherapy for Outpatients With Schizophrenia
Brief Summary	The purpose of this research study is to determine whether a new drug for schizophrenia is better for the maintenance treatment than a standard drugs currently prescribed. The new medication is called quetiapine and it will be compared with a standard medication called haloperidol decanoate. The study will determine if quetiapine causes fewer problems than haloperidol with side effects such as stiffness and restlessness and whether it costs the VA more or less to treat patients with quetiapine. In addition, blood samples will be collected every three months to determine if certain chemicals in the blood can influence the outcome of the subjects' illness.
Detailed Description
Study Phase
Study Type ^†	Interventional
Study Design ^†	Treatment, Randomized, Uncontrolled, Parallel Assignment, Efficacy Study
Primary Outcome Measure ^†
Secondary Outcome Measure ^†
Condition ^†	Schizophrenia Schizoaffective Disorder
Intervention ^†	Drug: quetiapine Drug: haloperidol decanoate
MEDLINE PMIDs
Links

Recruitment Information Fields
Recruitment Status ^†	Completed
Enrollment ^†
Start Date ^†	April 1997
Completion Date	March 2002
Eligibility Criteria ^†	Inclusion Criteria Schizophrenia or Schizoaffective Disorder diagnosed by DSM-IV Between the ages 18-60. A candidate for maintenance antipsychotic therapy. This means that patients will have had at least two documented episodes of acute schizophrenic illness or at least two years of continuing psychotic symptoms. Exclusion Criteria Organic brain disease. Mental Retardation Chronic medical illness which would make antipsychotic medication inappropriate.
Gender	Both
Ages	18 Years to 60 Years
Accepts Healthy Volunteers	No
Contacts ^††
Location Countries ^†	United States

Administrative Information Fields
NCT ID ^†	NCT00018642
Organization ID	MHBS-042-96F
Secondary IDs ^††
Study Sponsor ^†	Department of Veterans Affairs
Collaborators ^††
Investigators ^†
Information Provided By	Department of Veterans Affairs
Verification Date	December 2004
First Received Date ^†	July 3, 2001
Last Updated Date	June 23, 2005

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.